Amitriptyline

Generic Name: Amitriptyline

Brand Names: Elavil

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₃N

CAS Number: 50-48-6

Unique Ingredient Identifier: 1806D8D52K

Background: Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.

Indication: This drug in indicated for the following conditions :

Major depressive disorder in adults

Management of neuropathic pain in adults

Prophylactic treatment of chronic tension-type headache (CTTH) in adults

Prophylactic treatment of migraine in adults
...

Associated Conditions: Anorexia Nervosa (AN), Attention Deficit Hyperactivity Disorder (ADHD), Bulimia Nervosa, Depression, Depression Acute, Diabetic Neuropathies, Insomnia, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Migraine, Moderate Depression, Neuropathic Pain, Nocturnal Enuresis, Severe Depression, Sleep disorders and disturbances, Tension Headache, Moderate Agitation, Moderate Anxiety, Severe Anxiety, Severe agitation

Associated Therapies: -

Clinical Trials

Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome

Phase 4

Withdrawn

Conditions: Diarrhea- Predominant Irritable Bowel Syndrome
Quality of Life

Interventions: Drug: Mesalazine(asacol 800 mg)
Drug: Amitriptyline
Drug: placebo like amitriptyline
Drug: placebo like asacol

First Posted Date: 2014-07-15

Last Posted Date: 2016-04-15

Lead Sponsor: Tehran University of Medical Sciences

Registration Number: NCT02190526

Locations: 🇮🇷
Gastrointestinal Private Clinic, Tehran, Iran, Islamic Republic of

Alternative Dosing Regimens in the Pharmacotherapy of Insomnia

Phase 3

Terminated

Conditions: Insomnia

Interventions: Drug: Amitriptyline
Drug: Zolpidem
Drug: Placebo

First Posted Date: 2014-05-15

Last Posted Date: 2018-03-09

Lead Sponsor: Philipps University Marburg Medical Center

Target Recruit Count: 23

Registration Number: NCT02139098

Locations: 🇩🇪
Clinical Psychology and Psychotherapy, Department of Psychology, Philipps University Marburg, Marburg, Hessen, Germany

Pharmacological Conditioning of Sleep Patterns in Healthy Participants Using Amitriptylin

Not Applicable

Completed

Conditions: Healthy Participants

Interventions: Drug: Amitriptyline
Drug: Placebo

First Posted Date: 2014-05-01

Last Posted Date: 2014-09-03

Lead Sponsor: Winfried Rief

Registration Number: NCT02127736

Locations: 🇩🇪
Department of Psychology, Philipps University Marburg, Marburg, Hessen, Germany

Prediction of Migraine Prevention Efficacy Based on Individual's Pain Modulation

Not Applicable

Completed

Conditions: Migraine
Preventive Treatment

Interventions: Drug: placebo
Drug: Amitriptyline

First Posted Date: 2014-04-02

Last Posted Date: 2017-10-03

Lead Sponsor: Rambam Health Care Campus

Target Recruit Count: 54

Registration Number: NCT02101892

Locations: 🇮🇱
Rambam Health Care Campus, Haifa, Israel

Novel Topical Therapies for the Treatment of Genital Pain

Phase 2

Completed

Conditions: Female Genital Diseases

Interventions: Drug: placebo
Drug: Amitriptyline
Drug: Baclofen
Drug: Ketoprofen
Drug: Ketamine
Drug: Loperamide
Drug: Gabapentin

First Posted Date: 2014-03-28

Last Posted Date: 2016-07-15

Lead Sponsor: University of Rochester

Target Recruit Count: 9

Registration Number: NCT02099006

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States

Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines

Phase 4

Terminated

Conditions: Transformed Migraine
Chronic Daily Headache

Interventions: Procedure: SPG Block with 5% Lidocaine gel
Drug: Amitriptyline

First Posted Date: 2014-03-19

Last Posted Date: 2024-07-16

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 10

Registration Number: NCT02090998

Locations: 🇺🇸
Rutgers, Robert Wood Johnson Medical School , Pain Center of NJ, New Brunswick, New Jersey, United States

Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: ETS6103 (high dose)
Drug: ETS6103 (low dose)
Drug: Amitriptyline

First Posted Date: 2013-12-18

Last Posted Date: 2017-01-11

Lead Sponsor: e-Therapeutics PLC

Target Recruit Count: 164

Registration Number: NCT02014363

Locations: 🇬🇧
CPS Research, Glasgow, Scotland, United Kingdom

Interpersonal Psychotherapy for Treatment Resistant Depression

First Posted Date: 2013-07-11

Last Posted Date: 2013-07-11

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 74

Registration Number: NCT01896349

Locations: 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

Effect of Minocycline on Pain Caused by Nerve Damage

Phase 4

Completed

Conditions: Neuropathic Pain Caused by Lumbar Radicular Pain

Interventions: Drug: placebo
Drug: Amitriptyline
Drug: Minocycline

First Posted Date: 2013-06-05

Last Posted Date: 2015-01-27

Lead Sponsor: Ziekenhuis Oost-Limburg

Target Recruit Count: 60

Registration Number: NCT01869907

Locations: 🇧🇪
Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium

Amitriptyline to Prevent Headache After Traumatic Brain Injury

Phase 2

Completed

Conditions: Brain Injuries
Post-Traumatic Headache

Interventions: Drug: Amitriptyline

First Posted Date: 2013-05-17

Last Posted Date: 2022-01-31

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT01856270

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy